PR Newswire BiotechOriginal article
Link Cell Therapies Initiates Clinical Dosing with Logic-Gated CAR-T Therapy, Expands Executive Leadership, and Upsizes Series A Financing to $90 Million
Phase 1LNK001Positive
AI Analysis
Summary
Link Cell Therapies initiated clinical dosing of LNK001, an AND-gated CAR-T therapy targeting CAIX and ENPP3, in a Phase 1 study for advanced clear cell renal cell carcinoma at MD Anderson Cancer Center, while completing a $90 million Series A financing round and announcing new executive leadership.
Clinical Trial Data
Phase
1
Outcome Details
Clinical dosing initiated in Phase 1 study
Importance:6/10
Sentiment:
0.70
CAR-TPhase 1renal cell carcinomaSeries A financingexecutive appointmentslogic-gated therapy
Related Companies
Read the original article
Published by PR Newswire Biotech on September 28, 2026 10:59 AM